Clinical pharmacology of the serotonin receptor agonist, zolmitriptan (Q37008907)

17 August 2017

1 reference

title

Clinical pharmacology of the serotonin receptor agonist, zolmitriptan (English)

1 reference

17 August 2017

0 references

1 reference

B Lee Peterlin

1

1 reference

17 August 2017

Alan M Rapoport

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

17 August 2017

published in

1 reference

17 August 2017

volume

3

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

899-911

1 reference

Serotonin 5-HT1B/1D Receptor Agonists in Migraine

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

5-Hydroxytryptamine and the pathophysiology of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

21 January 2018

Zolmitriptan (Zomig).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Clinical applications of new therapeutic deliveries in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan nasal spray: advances in migraine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Review of zolmitriptan and its clinical applications in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Pregnancy outcome following prescription for sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Efficacy of zolmitriptan nasal spray in adolescent migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan provides consistent migraine relief when used in the long-term

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan versus sumatriptan comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Oral zolmitriptan is effective in the acute treatment of cluster headache.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Acute management of migraine: triptans and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.6.899

21 January 2018

Identifiers

DOI

10.1517/17425255.3.6.899

1 reference

17 August 2017

1 reference